Calcineurin Inhibitor Replacement With Mammalian Target of Rapamycin (mTOR) Inhibitor Following Lung Transplantation
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70211 ↗At a glance
Journal article in Clinical Transplantation, 2025. Written by Kavya Kommaraju and 3 co-authors. Institution: Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Lung Transplantation, Calcineurin Inhibitors, Graft Rejection, Immunosuppressive Agents. Cited 2 times so far (Crossref); 19 references.
Abstract (original language)
Introduction
Calcineurin inhibitors (CNIs) are the cornerstone of lung transplant immunosuppression but are associated with nephrotoxicity and other adverse effects. Although dose reduction and combination with Sirolimus, a mammalian target of rapamycin inhibitor (mTORi), have been explored, full conversion to Sirolimus remains uncommon. This study describes the characteristics and outcomes of lung transplant recipients who underwent complete CNI withdrawal and conversion to Sirolimus.
Methods
This retrospective case series included 52 lung transplant recipients transitioned to Sirolimus‐based immunosuppression between 2010 and 2021. Data on demographics, transplant characteristics, immunosuppression, and outcomes were collected from electronic medical records.
Results
The cohort included 31 males (59.6%) with a median age of 58.4 years (IQR 52.3–63.5). The primary indication for CNI withdrawal was renal dysfunction (73.1%). Sirolimus discontinuation occurred in 69.2%, most commonly due to edema (25.0%), lung toxicity (19.4%), rejection (19.4%), and surgical needs (22.2%). Clinically significant rejection occurred in 13.5%, with four patients progressing to chronic lung allograft dysfunction (CLAD) and two deaths. Sixteen patients (30.8%) tolerated CNI withdrawal for over a year.
Conclusion
Full conversion from CNI to Sirolimus is poorly tolerated due to side effects and has a high incidence of rejection. Further studies are needed to optimize patient selection and risk mitigation strategies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ORCID profiles: Kelly M Pennington
Cite
APA
Kommaraju, K., Alsharif, M., Scott, J. P., & Pennington, K. M. (2025). Calcineurin Inhibitor Replacement With Mammalian Target of Rapamycin (mTOR) Inhibitor Following Lung Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.70211
Vancouver
Kommaraju K, Alsharif M, Scott JP, Pennington KM. Calcineurin Inhibitor Replacement With Mammalian Target of Rapamycin (mTOR) Inhibitor Following Lung Transplantation. Clinical Transplantation. 2025. doi:10.1111/ctr.70211
BibTeX
@article{Kommaraju2025,
author = {Kommaraju, Kavya and Alsharif, Muath and Scott, John P and Pennington, Kelly M},
title = {Calcineurin Inhibitor Replacement With Mammalian Target of Rapamycin (mTOR) Inhibitor Following Lung Transplantation},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70211}
}
EUVIMED